Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 6087-6095

  Konduri, Santhi D ^a,b,c   Ticku, Jonathan ^c   Bobustuc, George C ^a,c   Sutphin, Robert M ^a,c   Colon, Jimmie ^a,c   Isley, Beth ^a,c   Bhakat, Kishor K ^d   Kalkunte, Srivenugopal S ^e   Baker, Cheryl H ^a,b,c  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^c ORLANDO HEALTH   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; CYCLIN A; CYCLIN B1; CYCLIN B2; CYCLIN DEPENDENT KINASE INHIBITOR 1; GEMCITABINE; KI 67 ANTIGEN; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P21; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL PROLIFERATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, P53; GUANINE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 70349690451     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0887     Document Type: Article

References (45)

1. Kornmann M, Beger HG, Link KH. Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer. Recent Results Cancer Res 2003;161:180-195
2. Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs 2000;59:1071-1089 (Pubitemid 30339131)
3. Zalatnai A. Review: potential role of cell cycle synchronizing agents in combination treatment modalities of malignant tumors. In vivo 2005; 19:85-91. (Pubitemid 40450381)
4. Evans DBAJ, Rich TA, Devita VT, Hellman S, Rosenberg AS. Cancer of the pancreas. Cancer. Philadelphia: J.B. Lippincott Co.; 1997.
5. Osanai T, Takagi Y, Toriya Y, et al. Inverse correlation between the expression of O6-methylguanine- DNA methyl transferase (MGMT) and p53 in breast cancer. Jpn J Clin Oncol 2005;35:121-125 (Pubitemid 40514540)
6. Ito Y, Takeda T, Wakasa K, Tsujimoto M, Okada M, Matsuura N. Expression of the G2-M modulators in pancreatic adenocarcinoma. Pancreatology 2002;2:138-145 (Pubitemid 34639089)
7. Innocente SA, Abrahamson JL, Cogswell JP, Lee JM. p53 regulates a G2 checkpoint through cyclin B1. Proc Natl Acad Sci U S A 1999;96:2147-2152
8. Taylor WR, DePrimo SE, Agarwal A, et al. Mechanisms of G2 arrest in response to over-expression of p53. Mol Biol Cell 1999;10:3607-3622 (Pubitemid 29534013)
9. Krause K, Wasner M, Reinhard W, et al. The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res 2000;28: 4410-4418 (Pubitemid 30838236)
10. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331
11. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054-1072
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
13. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003;22: 7414-7430 (Pubitemid 37487167)
14. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432:307-315
15. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-885 (Pubitemid 41746032)
16. Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 2005;57:187-215. (Pubitemid 41043884)
17. Reed JC. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol 2006; 3:388-398
18. Taghavi MH, Davoodi J. Restoration of p53 functions suppresses tumor growth of pancreatic cells with different p53 status. Cancer Biother Radiopharm2007;22:322-332
19. Taghavi MH, Davoodi J, Mirshahi M. The effect of wild type P53 gene transfer on growth properties and tumorigenicity of PANC-1 tumor cell line. Iran Biomed J 2007;11:1-6. (Pubitemid 46263053)
20. Konduri S, Colon J, Baker CH, et al. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 2009;8: 533-542
21. Biswas T, Ramana CV, Srinivasan G, et al. Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone. Oncogene 1999;18:525-532 (Pubitemid 29060628)
22. Gong J, Ammanamanchi S, Ko TC, BrattainMG. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells. Cancer Res 2003;63:3340-3346
23. Liu W, Konduri SD, Bansal S, et al. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem2006;281:9837-9840
24. Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM. Estrogen receptor α inhibits p53- mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res 2007; 67:7746-7755 (Pubitemid 47281368)
25. Baker CH, Kedar D, McCarty MF, et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002;161:929-938 (Pubitemid 34988380)
26. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002;62:1996-2003. (Pubitemid 34408443)
27. Kokkinakis DM, Ahmed MM, Delgado R, Fruitwala MM, Mohiuddin M, Albores-Saavedra J. Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents. Cancer Res 1997;57: 5360-5368 (Pubitemid 27516375)
28. Bobola MS, Berger MS, Silber JR. Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines. Mol Carcinog 1995;13:81-88
29. Bobola MS, Blank A, Berger MS, Silber JR. Contribution of O6-methylguanine-DNA methyltransferase to monofunctional alkylating-agent resistance in human brain tumor-derived cell lines. Mol Carcinog 1995;13:70-80.
30. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996;56:783-788 (Pubitemid 26055468)
31. Silber JR, Blank A, Bobola MS, Ghatan S, Kolstoe DD, Berger MS. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 1999;5:807-814 (Pubitemid 29180832)
32. Tanaka S, Kobayashi I, Utsuki S, et al. O6- methylguanine-DNA methyltranspherase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas. Int J Cancer 2003;103:67-72. (Pubitemid 35424207)
33. Kokkinakis DM, Liu X, Neuner RD. Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): implications to the therapy of pancreatic adenocarcinoma. Mol Cancer Ther 2005;4:1338-1348
34. Natsume A, Wakabayashi T, Ishii D, et al. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol 2008;61:653-659
35. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A 1990; 87:5368-5372 (Pubitemid 20260181)
36. Bertino JR. Transfer of drug resistance genes into hematopoietic stem cells for marrow protection. Oncologist 2008;13:1036-1042
37. Davis BM, Koc ON, Reese JS, Gerson SL. O6-benzylguanine-resistant mutant MGMT genes improve hematopoietic cell tolerance to alkylating agents. Prog Exp Tumor Res 1999; 36:65-81.
38. DerghamST, Dugan MC, Joshi US, et al. The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenocarcinoma. Cancer 1997;80:372-381 (Pubitemid 27323406)
39. Hu YX, Watanabe H, Ohtsubo K, et al. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 1997;3:1473-1477 (Pubitemid 27431553)
40. Lu CD, Morita S, Ishibashi T, Hara H, Isozaki H, Tanigawa N. Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer 1999;85:1250-1260 (Pubitemid 29125077)
41. Lew DJ, Dulic V, Reed SI. Isolation of three novel hum an cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 1991;66:1197-1206 (Pubitemid 121001409)
42. Dunn WC, Foote RS, Hand RE, Jr., Mitra S. Cell cycle-dependent modulation of O6-methylguanine- DNA methyltransferase in C3H/10T1/2 cells. Carcinogenesis 1986;7:807-812 (Pubitemid 17126068)
43. Yan L, Donze JR, Liu L. Inactivated MGMT by O6-benzylguanine is associated with prolonged G2/M arrest in cancer cells treated with BCNU. Oncogene 2005;24:2175-2183 (Pubitemid 40516584)
44. Fishel ML, Newell DR, Griffin RJ, et al. Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity. J Pharmacol Exp Ther 2005;312: 206-213 (Pubitemid 40096470)
45. Niture SK, Doneanu CE, Velu CS, Bailey NI, Srivenugopal KS. Proteomic analysis of human O6-methylguanine-DNA methyltransferase by affinity chromatography and tandem mass spectrometry. Biochem Biophys Res Commun 2005; 337:1176-1184 (Pubitemid 41505248)